Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial
Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss drug market. U.S.-listed shares fell over 5% on Monday to a four-year low around $45, continuing a downward spiral that has seen the company lose nearly half its value since the beginning of 2025. A leading factor … Read more